Bharat Immunologicals & Biologicals Corporation (BIBCL) Fair Value & Analysis
Healthcare · IN · Market cap ₹725M
Fair value as of: Jul 5, 2026
From 7 valuation models · updated today
Share price −2.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹14.25 – ₹23.80 · fair‑value band ₹2.11 – ₹17.61 · the ₹16.79 price screens above the ₹9.86 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Bharat Immunologicals & Biologicals Corporation (BIBCL) currently trades at ₹16.79, while our model-based Fair Value estimate is ₹9.86 — implying the stock looks roughly 41.3% overvalued today. We read business quality at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at ₹76.5M. It earns a return on equity of -21.0%. Net debt stands at ₹689M. Fundamentals as of Jul 5, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Bharat Immunologicals & Biologicals Corporation Limited, a biotechnology company, engages in the manufacture and sale of pharmaceutical products in India. It offers oral polio vaccines, zinc tablets, diarrhea management kits, and BIB sweet tablets. The company was incorporated in 1989 and is based in Bulandshahr, India.
Revenue & earnings trend
FY2019 – FY2023 · reported fiscal years
Bharat Immunologicals & Biologicals Corporation reported revenue of ₹446M in FY2023 versus ₹836M in FY2019, a compound −14.5%/yr. Reported net income was −₹166M in FY2023.
Is BIBCL fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $618.03 | $594.40 | -4% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $303.64 | $110.31 | -64% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bharat Immunologicals & Biologicals Corporation (BIBCL) undervalued?
What is the fair value of BIBCL?
What is the quality score of BIBCL?
What is the revenue of Bharat Immunologicals & Biologicals Corporation (BIBCL)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.